Article: Nicotinamide Riboside Restores Heart Energy and Function in Heart Failure: Preclinical Findings

PrevNext
Cardiovascular Disease Cardiovascular Health Preclinical

Nicotinamide Riboside Restores Heart Energy and Function in Heart Failure: Preclinical Findings

Synopsis

More than half of people with heart failure have a condition called heart failure with preserved ejection fraction (HFpEF), but its causes are not well understood and current treatments are limited. This study found that hearts affected by HFpEF show high levels of protein acetylation—especially in mitochondria, where energy is produced—and a reduced NAD+/NADH ratio, leading to poor energy metabolism. In a mouse model of HFpEF, researchers treated the animals with nicotinamide riboside (NR), a precursor of NAD+, for 30 days. The treatment restored the NAD+/NADH balance, reduced excessive acetylation, improved mitochondrial energy production, and alleviated heart dysfunction. These results suggest that metabolic imbalance and NAD+ depletion play key roles in HFpEF and that NR supplementation could be a promising way to improve heart function and energy metabolism in this condition.

Journal

Journal of Molecular and Cellular Cardiology

Share

Read more

Metabolic Health

Nicotinamide Riboside Has Minor Metabolic Benefits in Obesity: Preclinical Findings

SynopsisNicotinamide riboside supplements (NRS) are thought to boost NAD+ levels and mitochondrial function, potentially improving muscle health and energy use. This study tested NRS effects in nor...

Read more
Cellular Health

Nicotinamide Riboside Suppresses Coronavirus Replication: Preclinical Findings

Synopsis Viruses like SARS-CoV-2, which causes COVID-19, rely on the host’s metabolism to reproduce. This study used a related coronavirus model in mice to explore how metabolic interventions coul...

Read more